Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nortiva Bio Inc. maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently manages 5 pending office actions. These actions are distributed across 4 distinct art units, suggesting a range of technical subject matter within its pharmaceutical and biological filings.
The prosecution workload involves 4 distinct examiners. PEEBLES, KATHERINE is the busiest examiner for the company, currently overseeing 2 pending office actions. This concentration shows that while the company deals with multiple examiners, a portion of its 5 pending office actions is handled by a single individual.
With 5 pending office actions and 4 distinct art units, the company's prosecution strategy is spread across several specialized groups. The presence of 4 distinct examiners for these 5 actions indicates that most matters are being reviewed independently, with the exception of the 2 pending office actions assigned to PEEBLES, KATHERINE. This distribution requires the company to manage multiple examiner-specific approaches simultaneously within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PEEBLES, KATHERINE | 2 | 35.5% | +48.6% |
| SONG, INJA | 1 | 66.4% | +48.8% |
| SCHMITT, MICHAEL J | 1 | 56.8% | +20.7% |
| GREENE, IVAN A | 1 | 18.7% | +6.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18637281 | GEOMETRIC CONFIGURATIONS FOR GASTRIC RESIDENCE SYSTEMS | SONG, INJA | — |
| 17774128 | POLYMERIC LINKERS FOR A GASTRIC RESIDENCE SYSTEM | GREENE, IVAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272786 | GASTRIC RESIDENCE SYSTEMS FOR ADMINISTRATION OF RISPERIDONE | PEEBLES, KATHERINE | 88d overdue |
| 18731125 | MANUFACTURING METHODS FOR GASTRIC RESIDENCE SYSTEMS | PEEBLES, KATHERINE | — |
| 18637281 | GEOMETRIC CONFIGURATIONS FOR GASTRIC RESIDENCE SYSTEMS | SONG, INJA | — |
| 18289331 | GASTRIC RESIDENCE SYSTEMS COMPRISING BUPRENORPHINE AND NALOXONE | SCHMITT, MICHAEL J | — |
| Art Unit | Apps |
|---|---|
| 1617 | 2 |
| 3783 | 1 |
| 1629 | 1 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18731125 | MANUFACTURING METHODS FOR GASTRIC RESIDENCE SYSTEMS | PEEBLES, KATHERINE | 1617 | §102§103§112DP | Non-Final OA | — | Pending | May 31, 2024 |
| 18637281 | GEOMETRIC CONFIGURATIONS FOR GASTRIC RESIDENCE SYSTEMS | SONG, INJA | 3783 | §102§103§112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18289331 | GASTRIC RESIDENCE SYSTEMS COMPRISING BUPRENORPHINE AND NALOXONE | SCHMITT, MICHAEL J | 1629 | §103 | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18272786 | GASTRIC RESIDENCE SYSTEMS FOR ADMINISTRATION OF RISPERIDONE | PEEBLES, KATHERINE | 1617 | DP | Final Rejection | 88d overdue | Pending | Jul 17, 2023 |
| 17774128 | POLYMERIC LINKERS FOR A GASTRIC RESIDENCE SYSTEM | GREENE, IVAN A | 1619 | §103 | Non-Final OA | — | Pending | May 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial